Artal Group Sa Lifted Its Stake in Atara Biotherapeutics (ATRA) by $1.60 Million; Washington Trust Company Lowered Its Bank Of America (BAC) Stake by $949,225 as Share Value Declined

January 14, 2018 - By Winifred Garcia

Artal Group Sa increased its stake in Atara Biotherapeutics Inc (ATRA) by 20% based on its latest 2017Q3 regulatory filing with the SEC. Artal Group Sa bought 100,000 shares as the company’s stock declined 2.88% while stock markets rallied. The institutional investor held 600,000 shares of the health care company at the end of 2017Q3, valued at $9.93M, up from 500,000 at the end of the previous reported quarter. Artal Group Sa who had been investing in Atara Biotherapeutics Inc for a number of months, seems to be bullish on the $864.33M market cap company. The stock increased 27.54% or $6.1 during the last trading session, reaching $28.25. About 3.69 million shares traded or 708.01% up from the average. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has declined 7.28% since January 14, 2017 and is downtrending. It has underperformed by 23.98% the S&P500.

Washington Trust Company decreased its stake in Bank Of America Corp (BAC) by 3.03% based on its latest 2017Q3 regulatory filing with the SEC. Washington Trust Company sold 37,969 shares as the company’s stock declined 6.00% while stock markets rallied. The institutional investor held 1.22M shares of the major banks company at the end of 2017Q3, valued at $30.82 million, down from 1.25 million at the end of the previous reported quarter. Washington Trust Company who had been investing in Bank Of America Corp for a number of months, seems to be less bullish one the $325.33 billion market cap company. The stock increased 1.73% or $0.53 during the last trading session, reaching $31.19. About 66.37M shares traded. Bank of America Corporation (NYSE:BAC) has risen 58.64% since January 14, 2017 and is uptrending. It has outperformed by 41.94% the S&P500.

Among 32 analysts covering Bank of America (NYSE:BAC), 21 have Buy rating, 0 Sell and 11 Hold. Therefore 66% are positive. Bank of America had 103 analyst reports since July 21, 2015 according to SRatingsIntel. The stock of Bank of America Corporation (NYSE:BAC) earned “Neutral” rating by Citigroup on Tuesday, April 4. Macquarie Research upgraded the shares of BAC in report on Tuesday, August 25 to “Underperform” rating. The stock of Bank of America Corporation (NYSE:BAC) earned “Buy” rating by Vetr on Tuesday, August 11. As per Thursday, April 7, the company rating was maintained by JP Morgan. The firm has “Hold” rating by Societe Generale given on Tuesday, September 13. Societe Generale downgraded it to “Hold” rating and $33.0 target in Tuesday, January 9 report. The firm has “Outperform” rating by CLSA given on Friday, January 29. On Tuesday, June 6 the stock rating was maintained by Jefferies with “Buy”. The rating was maintained by RBC Capital Markets with “Buy” on Wednesday, August 30. As per Wednesday, January 11, the company rating was upgraded by Societe Generale.

Washington Trust Company, which manages about $1.68 billion US Long portfolio, upped its stake in Schein Henry (NASDAQ:HSIC) by 43,414 shares to 68,026 shares, valued at $5.58 million in 2017Q3, according to the filing. It also increased its holding in Washington Trust Bancorp Inc (NASDAQ:WASH) by 6,011 shares in the quarter, for a total of 487,012 shares, and has risen its stake in Honeywell Intl Inc (NYSE:HON).

Investors sentiment decreased to 1.04 in 2017 Q3. Its down 0.08, from 1.12 in 2017Q2. It is negative, as 68 investors sold BAC shares while 569 reduced holdings. 117 funds opened positions while 547 raised stakes. 6.91 billion shares or 9.01% more from 6.34 billion shares in 2017Q2 were reported. Rockefeller Finance, New York-based fund reported 42,951 shares. Sigma Planning Corporation holds 0.35% in Bank of America Corporation (NYSE:BAC) or 165,438 shares. Jpmorgan Chase & has 182.13M shares for 1.02% of their portfolio. Mount Vernon Assoc Md has invested 3.7% of its portfolio in Bank of America Corporation (NYSE:BAC). Qs Investors Llc invested in 519,349 shares. Graham Cap LP invested 0.32% in Bank of America Corporation (NYSE:BAC). Florida-based Sawgrass Asset Mngmt Ltd Liability Corp has invested 0.04% in Bank of America Corporation (NYSE:BAC). Washington Com has invested 1.83% in Bank of America Corporation (NYSE:BAC). The Illinois-based Interocean Cap Limited Com has invested 1.2% in Bank of America Corporation (NYSE:BAC). Community Fincl Bank Na holds 0.01% or 5,360 shares in its portfolio. Moreover, Public Employees Retirement Association Of Colorado has 0.33% invested in Bank of America Corporation (NYSE:BAC). Exxonmobil Mgmt Tx accumulated 1.79M shares. Synovus Corporation, Georgia-based fund reported 609,666 shares. Brandywine Tru owns 13,326 shares. Cv Starr invested in 96,726 shares.

Analysts await Bank of America Corporation (NYSE:BAC) to report earnings on January, 17 before the open. They expect $0.46 earnings per share, up 15.00% or $0.06 from last year’s $0.4 per share. BAC’s profit will be $4.80B for 16.95 P/E if the $0.46 EPS becomes a reality. After $0.48 actual earnings per share reported by Bank of America Corporation for the previous quarter, Wall Street now forecasts -4.17% negative EPS growth.

Since August 10, 2017, it had 0 insider purchases, and 1 insider sale for $2.10 million activity.

Among 6 analysts covering Atara Biotherapeutics (NASDAQ:ATRA), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Atara Biotherapeutics had 18 analyst reports since September 9, 2015 according to SRatingsIntel. On Tuesday, December 15 the stock rating was maintained by JMP Securities with “Market Outperform”. The firm has “Outperform” rating given on Friday, October 9 by William Blair. Goldman Sachs initiated Atara Biotherapeutics, Inc. (NASDAQ:ATRA) on Wednesday, November 18 with “Neutral” rating. The firm has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. Jefferies maintained it with “Buy” rating and $30.0 target in Thursday, August 31 report. Citigroup upgraded Atara Biotherapeutics, Inc. (NASDAQ:ATRA) on Wednesday, January 3 to “Neutral” rating. The firm has “Sell” rating by Citigroup given on Tuesday, December 15. Citigroup maintained it with “Sell” rating and $8 target in Friday, August 19 report. The company was initiated on Wednesday, September 9 by Canaccord Genuity. The stock of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) earned “Sell” rating by Goldman Sachs on Thursday, September 15.

Since August 10, 2017, it had 0 buys, and 14 selling transactions for $999,963 activity. Another trade for 7,604 shares valued at $112,159 was made by Haqq Christopher on Tuesday, August 15. $64,526 worth of stock was sold by Ciechanover Isaac E. on Thursday, August 10. 1,184 shares were sold by Gallagher Carol Giltner, worth $16,931. On Tuesday, August 15 the insider MCGRATH JOHN sold $60,102. Clark Mitchall G. also sold $43,291 worth of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) shares.

Investors sentiment increased to 1.54 in Q3 2017. Its up 0.26, from 1.28 in 2017Q2. It improved, as 8 investors sold ATRA shares while 16 reduced holdings. 9 funds opened positions while 28 raised stakes. 26.16 million shares or 3.51% more from 25.27 million shares in 2017Q2 were reported. Tower Rech Cap Limited (Trc) holds 1,253 shares or 0% of its portfolio. Baupost Grp Inc Lc Ma accumulated 5.36 million shares. Old West Investment Management Ltd has 20,895 shares. Blackrock invested in 0% or 1.99M shares. The New York-based Bridger Mgmt Limited Liability Com has invested 1.64% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Redmile Grp Lc has 2.36% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 2.89 million shares. Nationwide Fund Advsr holds 0% in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) or 13,467 shares. Ameritas Inv Prtnrs Inc owns 0% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 1,810 shares. Metropolitan Life Insur accumulated 17,716 shares. Dekabank Deutsche Girozentrale accumulated 0% or 9,200 shares. Moreover, Legal & General Public Ltd Com has 0% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Northern Tru Corp invested 0% of its portfolio in Atara Biotherapeutics, Inc. (NASDAQ:ATRA). Alyeska Grp Limited Partnership, Illinois-based fund reported 174,868 shares. Raymond James & Assoc reported 23,606 shares. Millennium Limited Liability Corp owns 0% invested in Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for 21,714 shares.

Artal Group Sa, which manages about $5.81B US Long portfolio, decreased its stake in Seres Therapeutics Inc by 50,000 shares to 550,000 shares, valued at $8.82 million in 2017Q3, according to the filing. It also reduced its holding in Neurocrine Biosciences Inc (NASDAQ:NBIX) by 150,000 shares in the quarter, leaving it with 400,000 shares, and cut its stake in Citigroup Inc (Call) (NYSE:C).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: